Home » Stocks » BLPH

Bellerophon Therapeutics, Inc. (BLPH)

Stock Price: $4.71 USD 0.14 (3.06%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
Market Cap 44.78M
Revenue (ttm) n/a
Net Income (ttm) -25.22M
Shares Out 9.49M
EPS (ttm) -2.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $4.71
Previous Close $4.57
Change ($) 0.14
Change (%) 3.06%
Day's Open 4.62
Day's Range 4.55 - 4.78
Day's Volume 96,764
52-Week Range 3.79 - 14.09

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

WARREN, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments f...

2 weeks ago - GlobeNewsWire

Dr. Amin Has Served as an Independent Director Since 2015 and Succeeds Jonathan Peacock Following Mr. Peacock's Retirement from the Company's Board Dr. Amin Has Served as an Independent Director Since 2...

2 weeks ago - GlobeNewsWire

WARREN, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments f...

1 month ago - GlobeNewsWire

WARREN, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments...

3 months ago - GlobeNewsWire

WARREN, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments ...

5 months ago - GlobeNewsWire

WARREN, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments ...

6 months ago - GlobeNewsWire

WARREN, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments ...

6 months ago - GlobeNewsWire

WARREN, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments ...

7 months ago - GlobeNewsWire

Bellerophon Therapeutics (BLPH) delivered earnings and revenue surprises of -2.44% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the ...

7 months ago - Zacks Investment Research

WARREN, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments ...

7 months ago - GlobeNewsWire

WARREN, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments ...

7 months ago - GlobeNewsWire

WARREN, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatmen...

8 months ago - GlobeNewsWire

WARREN, N.J., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatment...

10 months ago - GlobeNewsWire

WARREN, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatment...

10 months ago - GlobeNewsWire

Patients Treated with INOpulse® Demonstrated Improved Physical Activity Compared to Placebo

10 months ago - GlobeNewsWire

Initiation of the COViNOX Study Follows the Conclusion of the FDA Emergency Access Program Through Which 180 Patients with COVID-19 Were Treated in the United States Initiation of the COViNOX Study Foll...

10 months ago - GlobeNewsWire

WARREN, N.J., June 29, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infecti...

11 months ago - GlobeNewsWire

WARREN, N.J., May 22, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced the closing of its previously announced public offering an...

1 year ago - GlobeNewsWire

WARREN, N.J., May 19, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced the pricing of offerings for an aggregate of 3,076,923 sha...

1 year ago - GlobeNewsWire

WARREN, N.J., May 18, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced that it intends to offer and sell shares of its common sto...

1 year ago - GlobeNewsWire

WARREN, N.J., May 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments...

1 year ago - GlobeNewsWire

IND Submission Follows Completed Treatment of Several COVID-19 Patients with INOpulse Under FDA Authorized Emergency Expanded Access Program IND Submission Follows Completed Treatment of Several COVID-1...

1 year ago - GlobeNewsWire

Bellerophon Therapeutics: A Promising Solution To America's Ventilator Shortage During The COVID-19 Pandemic

1 year ago - Seeking Alpha

WARREN, N.J., April 01, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, closed its previously announc...

1 year ago - GlobeNewsWire

WARREN, N.J., March 30, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it has e...

1 year ago - GlobeNewsWire

The Food and Drug Administration has thrown a lifeline to a little known and beleaguered New Jersey therapeutics company, thrusting it into the search for Covid-19 treatments.

1 year ago - GuruFocus

Shares of micro-cap biotherapeutics company Bellerophon Therapeutics Inc (NASDAQ: BLPH) gap-opened higher Friday morning and were holding on to the gains during the trading session.

1 year ago - Benzinga

WARREN, N.J., March 20, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that the U.S....

1 year ago - GlobeNewsWire

WARREN, N.J., March 10, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the successfu...

1 year ago - GlobeNewsWire

Shares of biotherapeutics company Bellerophon Therapeutics Inc (NASDAQ: BLPH) were  more than doubling Tuesday following a positive clinical readout from the company.

1 year ago - Benzinga

WARREN, N.J., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced positive top-l...

1 year ago - GlobeNewsWire

WARREN, N.J., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the filing of ...

1 year ago - GlobeNewsWire

Shares of Bellerophon Therapeutics Inc. BLPH, +2.03% gained 38% in premarket trading on Tuesday after its experimental therapy to treat certain forms of pulmonary hypertension reported positive clinical...

1 year ago - Market Watch

Statistically Significant Improvement Demonstrated in Moderate to Vigorous Physical Activity

1 year ago - GlobeNewsWire

WARREN, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced positive initi...

1 year ago - GlobeNewsWire

Data Include New Results from Subgroup Analysis of Cohort 1 Further Demonstrating Benefits of INOpulse Data Include New Results from Subgroup Analysis of Cohort 1 Further Demonstrating Benefits of INOpulse

1 year ago - GlobeNewsWire

According to these filters, the following are significant trades from company insiders this month.

Other stocks mentioned: BRP, CMCSA, OPK, PGNY, STON
1 year ago - GuruFocus

Results Presented in Late-Breaking Abstract as an Oral Presentation Presentation Will Also be Published in the Highlights from CHEST Special Edition

1 year ago - GlobeNewsWire

Results to be Presented in Late-Breaking Abstract as an Oral Presentation

1 year ago - GlobeNewsWire

WARREN, N.J., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, announced today the U.S. Food...

1 year ago - GlobeNewsWire

WARREN, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, announced today that Fabian T...

1 year ago - GlobeNewsWire

About BLPH

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hyp... [Read more...]

Industry
Biotechnology
IPO Date
Feb 13, 2015
CEO
Fabian Tenenbaum
Employees
21
Stock Exchange
NASDAQ
Ticker Symbol
BLPH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for BLPH stock is "Buy." The 12-month stock price forecast is 21.33, which is an increase of 352.87% from the latest price.

Price Target
$21.33
(352.87% upside)
Analyst Consensus: Buy